GNRH1 and ovarian carcinoma: Trials of LH-RH agonists in ovarian cancer have shown objective response rates ranging from 6.6 to 17.4% in various studies with response durations of the order of a few months (Lind et al, 1992; Sevelda et al, 1992; Paskeviciute et al, 2002).